Search

everythinglearnresearchcommunity

for

Search:↓

Both Th1 and Th2 immune responses are increased in alopecia areata, with Th2 response more strongly linked to how severe the disease is.

Activating Nrf2 helps wounds heal faster by increasing hair follicle stem cells.

Topical tofacitinib is effective in promoting hair growth for non-scarring alopecia.

OCT can effectively screen and diagnose various medical conditions non-invasively.

Different scalp and hair disorders are more common in certain ethnic groups, with the most common being androgenetic alopecia, which is treated with medications like minoxidil and finasteride.

All four treatments for early rheumatoid arthritis had similar safety profiles.

The model and estimator can predict drug exposure in kidney transplant patients well.

The meeting highlighted the importance of genetic testing and multidisciplinary approaches in pediatric dermatology.

Alopecia Areata is an unpredictable autoimmune hair loss condition with limited and variable treatment effectiveness.

Methotrexate dose has little effect on its toxicity when used with adalimumab for early rheumatoid arthritis.

Dutasteride 0.5mg improves hair growth in 78% of people with hair loss, but may cause sexual problems in some.

Sulfotransferase SULT1A1 activity may predict minoxidil treatment success for hair loss.

Finasteride treatment lowers urine androgen and prostaglandin levels, making them potential markers for effectiveness.

Baricitinib 4 mg is effective and safe for treating severe alopecia areata.

Switching between the medications tofacitinib and baricitinib can be effective for treating hair loss in alopecia areata.

Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.

Topical tofacitinib cream may help treat certain hair loss conditions with fewer risks.

A woman with severe hair loss saw significant hair regrowth after adding platelet-rich plasma injections to her treatment with tofacitinib.

Baricitinib helped most teenagers with severe hair loss regrow hair and had mild side effects.

Alopecia areata involves complex immune and genetic factors, with potential treatment targets identified, but more research is needed.

COVID-19 vaccines may rarely worsen hair loss in people with severe alopecia, but the benefits of vaccination still outweigh this risk.

Ruxolitinib can cause a delayed skin reaction on the nose.

Blocking JAK3 signaling can reverse hair loss from alopecia areata.

JAK inhibitors are a promising new treatment for hair loss and nail problems in alopecia areata.

Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.

EGCG may help treat alopecia areata by blocking certain immune responses and reducing specific harmful immune cells.

A woman's complete hair loss condition improved after recovering from COVID-19.

Patients with rheumatoid arthritis using tofacitinib had more serious side effects than those with alopecia areata.

A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.

Topical ruxolitinib failed to regrow hair in a 66-year-old with alopecia areata.